Liquidia (NASDAQ:LQDA) Director Sells $280,000.00 in Stock

Liquidia Corporation (NASDAQ:LQDA) Director Arthur Kirsch sold 5,000 shares of the firm’s stock in a transaction that occurred on Tuesday, June 2nd. The stock was sold at an average price of $56.00, for a total transaction of $280,000.00. Following the sale, the director directly owned 10,000 shares of the company’s stock, valued at approximately $560,000. The trade was a 33.33% decrease in their position. The transaction was disclosed in a filing with the SEC, which is available at this hyperlink.

Liquidia Stock Performance

NASDAQ LQDA opened at $61.85 on Friday. The firm has a market cap of $5.50 billion, a price-to-earnings ratio of 441.82 and a beta of 0.58. The company has a 50 day moving average of $46.78 and a 200-day moving average of $39.56. The company has a current ratio of 2.22, a quick ratio of 2.03 and a debt-to-equity ratio of 1.18. Liquidia Corporation has a 1-year low of $11.85 and a 1-year high of $66.24.

Liquidia (NASDAQ:LQDA) last posted its quarterly earnings data on Monday, May 11th. The company reported $0.52 earnings per share for the quarter, topping the consensus estimate of $0.41 by $0.11. The company had revenue of $132.87 million during the quarter, compared to analyst estimates of $119.44 million. Liquidia had a net margin of 7.74% and a return on equity of 46.82%. The business’s revenue was up 4187.1% on a year-over-year basis. On average, equities analysts forecast that Liquidia Corporation will post 2.97 earnings per share for the current fiscal year.

Hedge Funds Weigh In On Liquidia

A number of hedge funds and other institutional investors have recently bought and sold shares of the business. Covestor Ltd boosted its stake in Liquidia by 41.9% in the fourth quarter. Covestor Ltd now owns 1,216 shares of the company’s stock valued at $42,000 after acquiring an additional 359 shares during the last quarter. PNC Financial Services Group Inc. boosted its stake in Liquidia by 7.2% in the fourth quarter. PNC Financial Services Group Inc. now owns 6,304 shares of the company’s stock valued at $217,000 after acquiring an additional 422 shares during the last quarter. Quantinno Capital Management LP boosted its stake in Liquidia by 3.6% in the first quarter. Quantinno Capital Management LP now owns 17,165 shares of the company’s stock valued at $648,000 after acquiring an additional 589 shares during the last quarter. Northwestern Mutual Wealth Management Co. bought a new position in Liquidia in the fourth quarter valued at approximately $25,000. Finally, ProShare Advisors LLC boosted its stake in Liquidia by 7.1% in the fourth quarter. ProShare Advisors LLC now owns 11,756 shares of the company’s stock valued at $405,000 after acquiring an additional 775 shares during the last quarter. 64.54% of the stock is owned by institutional investors.

Wall Street Analysts Forecast Growth

Several analysts have recently weighed in on the stock. Oppenheimer set a $75.00 price objective on shares of Liquidia in a report on Friday. HC Wainwright raised their price target on shares of Liquidia from $67.00 to $75.00 and gave the company a “buy” rating in a report on Friday. Jefferies Financial Group reissued a “buy” rating and issued a $60.00 price target on shares of Liquidia in a report on Monday, May 11th. Needham & Company LLC raised their price target on shares of Liquidia from $54.00 to $70.00 and gave the company a “buy” rating in a report on Monday, May 11th. Finally, BTIG Research raised their price target on shares of Liquidia from $50.00 to $59.00 and gave the company a “buy” rating in a report on Monday, May 11th. Three investment analysts have rated the stock with a Strong Buy rating, six have given a Buy rating and two have issued a Sell rating to the stock. Based on data from MarketBeat, the stock has a consensus rating of “Moderate Buy” and a consensus price target of $55.63.

Liquidia Company Profile

Liquidia Technologies, Inc is a clinical-stage biopharmaceutical company headquartered in Research Triangle Park, North Carolina. The company leverages its proprietary PRINT® (Particle Replication In Non-wetting Templates) platform to engineer precisely shaped and sized drug particles, with the goal of improving delivery, efficacy and safety profiles. By controlling particle characteristics at the nanoscale, Liquidia seeks to enhance respiratory and other therapies that depend on targeted delivery.

The company’s lead product candidate, LIQ861, is a dry powder formulation of treprostinil designed for inhalation in patients with pulmonary arterial hypertension (PAH).